SPY308.08+2.53 0.83%
DIA257.85+2.58 1.01%
IXIC9,608.38+56.33 0.59%

HC Wainwright & Co. Initiates Coverage On Revolution Medicines with Buy Rating, Announces Price Target of $55

HC Wainwright & Co. analyst Robert Burns initiates coverage on Revolution Medicines (NASDAQ:RVMD) with a Buy rating and announces Price Target of $55.

Benzinga · 05/21/2020 11:18

HC Wainwright & Co. analyst Robert Burns initiates coverage on Revolution Medicines (NASDAQ:RVMD) with a Buy rating and announces Price Target of $55.